



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 19 June 2018 (#19)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices:

- Early Registration Ends June 29 for Fall 2018 NIH Regional Seminar in San Francisco, CA ([NOT-OD-18-192](#))
- Notice to Extend the Expiration Date for PAR-15-356 "Major Opportunities for Research in Epidemiology of Alzheimer's Disease and Cognitive Resilience (R01)" ([NOT-AG-18-014](#))

1. Sustained Release Innovation for HIV (SRI) (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([RFA-AI-18-006](#))

Type: R61/R33

Application Due Date: November 30, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release drugs and drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals. This FOA requires an industry partner, milestones linked to Go/No-Go decisions and year 5 funding requires submission of a pre-IND application to the FDA.

Budget: Issuing IC and partner components intend to commit an estimated total of \$4.15M to fund 2-4 awards. Application budgets are limited to \$800,000 in direct costs per year for the R61 award phase and \$1,600,000 in direct costs per year for the R33 award phase. The total project period for an application submitted in response to this FOA cannot exceed five years. Applicants may request up to three years of support for the R61 phase, and up to two years of support for the R33 phase.

2. Immune Mechanisms at the Maternal-Fetal Interface (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([RFA-AI-18-023](#))

Type: R01

Application Due Date: October 4, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This initiative will support research to determine the roles and interactions of immune cells at the maternal-fetal interface throughout pregnancy, including mechanisms of responses to vaccination and infection, or ionizing radiation, that protect or impact the fetus and that may influence fetal immune system development.

Budget: NIAID intends to commit \$3.1M to fund 4-5 awards and NICHD intends to commit \$1M to fund 1-2 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed study should determine the project period. The maximum project period is 5 years.

3. Gastrointestinal Mechanisms Contributing to HIV Pathogenesis (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([RFA-DK-18-009](#))

Type: R01

Application Due Date: March 14, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks to bring together investigators with complementary expertise in HIV and in gastrointestinal mucosal pathobiology to dissect fundamental processes within the gastrointestinal tract that impact infection, persistence, and comorbidities. This multidisciplinary approach should lead to comprehensive, in-depth mechanistic analyses and advance progress toward alleviating comorbidities that afflict people living with HIV and toward developing a cure.

Budget: NIDDK intends to commit \$1,800,000 in FY 2019 to fund 2-3 awards. Application budgets are limited to \$500,000 direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Development of Novel Nonsteroidal Contraceptive Methods (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-HD-19-015\)](#)

Type: R61/R33

Application Due Date: November 6, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men and women that act prior to fertilization. This FOA aims to position innovative and validated methods for future clinical development.

Budget: The NICHD intends to commit \$3.0 million in FY 2018 to fund up to eight awards. For the R61 phase, Direct Costs may not exceed \$250,000 per year. For the R33 phase, Direct Costs may not exceed \$500,000 per year. The scope of the proposed project should determine the project period. The maximum project period of the combined R61 and R33 phases is up to 5 years with up to 2 years for the R61 phase and up to 3 years for the R33 phase. Applications with a project period of less than 5 years are encouraged where feasible.

5. Minor Use Minor Species Development of Drugs

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-827\)](#)

Type: R01

Application Due Date: August 27, 2018; January 18, 2019; August 16, 2019; January 17, 2020; August 14, 2020; January 15, 2021 by 11:59 PM Eastern Time Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop, or support the development of new animal drugs intended for minor use in major species or for use in minor species. The FDA is authorized to provide grants to assist in defraying the costs of qualified safety and effectiveness testing. Only entities developing drugs for veterinary use or parties working as research partners with such entities are eligible for grants. The organization (or applicant) seeking approval of the new animal drug under investigation must hold a minor use or minor species "designation" granted by FDA/CVM's Office of Minor Use and Minor Species Animal Drug Development (OMUMS) for that drug for a specified intended use, in accordance with the provisions of section 573 of the Food, Drug and Cosmetic Act (21 U.S.C. 360ccc-2) and 21 CFR part 516. FDA/CVM's Office of New Animal Drug Evaluation (ONADE) must have reviewed and accepted the proposed study protocol before an applicant can submit a grant application.

Budget: There are two levels of funding available. Grants will be awarded up to \$100,000 per year for up to 2 years, or up to \$150,000 per year for up to 3 years in certain cases. Please note the dollar limitation will apply to total costs, not direct costs. Applications for the smaller grants (\$100,000) may be for any routine safety or effectiveness study supportive of new animal drug approval or conditional approval of the designated product for the designated intended use. Study proposals for the larger grants (\$150,000) must be for necessary studies that are of unusual complexity, duration, or size. A third year of funding is available only for long-term toxicological studies. An application for a given study can only be submitted for one level of funding.

The nature and scope of the proposed research will vary from application to application; it is anticipated that the size and duration of each award will also vary. Although the financial plans of the FDA are to provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds.

The length of support of award project periods will depend on the nature of the study, but is one-year from date of award for most studies. For those studies with an expected duration of more than one year, a second, or in some cases, a third year of noncompetitive continuation of support will depend on the following factors:

(1) performance during the preceding year, (2) compliance with the regulatory requirements of an Investigational New Animal Drug File (INAD) and those associated with designation, and (3) availability of Federal funds.

The maximum project period is 3 years.

6. The Role of Epitranscriptomics in Development and Disease (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-830\)](#)

Type: R01

Application Due Date: November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020, June 3, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the participating ICs.

Budget: Application budgets should not exceed \$499,999 direct costs per year. Within that limit, applications need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

7. The Role of Epitranscriptomics in Development and Disease (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-831\)](#)

Type: R21

Application Due Date: November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020, June 3, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: *Christa* • Tel: 9838 • Email: cde.vries@sun.ac.za